TY - JOUR
T1 - Precision medicine
T2 - preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study
AU - Tsimberidou, Apostolia Maria
AU - Hong, David S.
AU - Fu, Siqing
AU - Karp, Daniel D.
AU - Piha-Paul, Sarina
AU - Kies, Merrill S.
AU - Ravi, Vinod
AU - Subbiah, Vivek
AU - Patel, Sunil M.
AU - Tu, Shi Ming
AU - Janku, Filip
AU - Heymach, John
AU - Johnson, Amber
AU - Cartwright, Carrie
AU - Zhao, Li
AU - Zhang, Jianhua
AU - Berry, Donald A.
AU - Vining, David J.
AU - Futreal, Andrew
AU - Miller, Vincent A.
AU - Meric-Bernstam, Funda
N1 - Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - Precision medicine is associated with favorable outcomes in selected patients with cancer. Herein, we report an interim analysis of IMPACT2, an ongoing randomized study evaluating genomic profiling and targeted agents in metastatic cancer. Patients with metastatic cancer underwent tumor genomic profiling (ClinialTrials.gov: NCT02152254), and 69 patients met the criteria for randomization. Tumor board and multidisciplinary review of molecular alterations optimized treatment selection. From 5/2014 to 4/2017, 320 patients (median age, 63 years; men, 47%) had tumor molecular aberrations, and 213 (66.56%) received anticancer therapy. The most frequently mutated genes were TP53 (42%), KRAS (16%), PIK3CA (12%), and CDKN2A (11%). The median OS was 10.9 months (95% CI, 8.8–12.9). OS was shorter in patients with higher tumor mutational burden. Independent factors associated with shorter OS were age ≥60 years, liver metastases, low albumin levels, high LDH levels, and KRAS and TP53 mutations. Outcomes for randomized patients will be reported after completion of the study.
AB - Precision medicine is associated with favorable outcomes in selected patients with cancer. Herein, we report an interim analysis of IMPACT2, an ongoing randomized study evaluating genomic profiling and targeted agents in metastatic cancer. Patients with metastatic cancer underwent tumor genomic profiling (ClinialTrials.gov: NCT02152254), and 69 patients met the criteria for randomization. Tumor board and multidisciplinary review of molecular alterations optimized treatment selection. From 5/2014 to 4/2017, 320 patients (median age, 63 years; men, 47%) had tumor molecular aberrations, and 213 (66.56%) received anticancer therapy. The most frequently mutated genes were TP53 (42%), KRAS (16%), PIK3CA (12%), and CDKN2A (11%). The median OS was 10.9 months (95% CI, 8.8–12.9). OS was shorter in patients with higher tumor mutational burden. Independent factors associated with shorter OS were age ≥60 years, liver metastases, low albumin levels, high LDH levels, and KRAS and TP53 mutations. Outcomes for randomized patients will be reported after completion of the study.
UR - http://www.scopus.com/inward/record.url?scp=85116956923&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85116956923&partnerID=8YFLogxK
U2 - 10.1038/s41698-021-00159-2
DO - 10.1038/s41698-021-00159-2
M3 - Article
C2 - 33742104
AN - SCOPUS:85116956923
SN - 2397-768X
VL - 5
JO - npj Precision Oncology
JF - npj Precision Oncology
IS - 1
M1 - 21
ER -